BHC vs. MLTX, MRUS, MRVI, JANX, RYTM, DYN, FOLD, RNA, ACAD, and MOR
Should you be buying Bausch Health Companies stock or one of its competitors? The main competitors of Bausch Health Companies include MoonLake Immunotherapeutics (MLTX), Merus (MRUS), Maravai LifeSciences (MRVI), Janux Therapeutics (JANX), Rhythm Pharmaceuticals (RYTM), Dyne Therapeutics (DYN), Amicus Therapeutics (FOLD), Avidity Biosciences (RNA), ACADIA Pharmaceuticals (ACAD), and MorphoSys (MOR). These companies are all part of the "pharmaceutical preparations" industry.
MoonLake Immunotherapeutics (NASDAQ:MLTX) and Bausch Health Companies (NYSE:BHC) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.
MoonLake Immunotherapeutics presently has a consensus price target of $74.46, suggesting a potential upside of 87.32%. Bausch Health Companies has a consensus price target of $11.33, suggesting a potential upside of 67.41%. Given Bausch Health Companies' stronger consensus rating and higher probable upside, equities analysts clearly believe MoonLake Immunotherapeutics is more favorable than Bausch Health Companies.
Bausch Health Companies received 303 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 77.42% of users gave MoonLake Immunotherapeutics an outperform vote while only 61.90% of users gave Bausch Health Companies an outperform vote.
In the previous week, MoonLake Immunotherapeutics had 4 more articles in the media than Bausch Health Companies. MarketBeat recorded 9 mentions for MoonLake Immunotherapeutics and 5 mentions for Bausch Health Companies. Bausch Health Companies' average media sentiment score of 0.34 beat MoonLake Immunotherapeutics' score of 0.19 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.
MoonLake Immunotherapeutics has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.
MoonLake Immunotherapeutics has a net margin of 0.00% compared to MoonLake Immunotherapeutics' net margin of -5.07%. Bausch Health Companies' return on equity of -7.92% beat MoonLake Immunotherapeutics' return on equity.
MoonLake Immunotherapeutics has higher earnings, but lower revenue than Bausch Health Companies. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.
93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Companies shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 8.1% of Bausch Health Companies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
MoonLake Immunotherapeutics beats Bausch Health Companies on 13 of the 17 factors compared between the two stocks.
Get Bausch Health Companies News Delivered to You Automatically
Sign up to receive the latest news and ratings for BHC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Bausch Health Companies Competitors List
Related Companies and Tools